Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATReceivables - Other
Ratios

Lipocine (LPCN) Non-Current Receivables (2021 - 2023)

Lipocine (LPCN) has disclosed Non-Current Receivables for 3 consecutive years, with $3.3 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Non-Current Receivables fell 19.69% year-over-year to $3.3 million, compared with a TTM value of $3.3 million through Jun 2023, down 19.69%, and an annual FY2022 reading of $3.3 million, down 19.69% over the prior year.
  • Non-Current Receivables was $3.3 million for Q2 2023 at Lipocine, roughly flat from $3.3 million in the prior quarter.
  • Across five years, Non-Current Receivables topped out at $4.0 million in Q4 2021 and bottomed at $3.3 million in Q3 2022.
  • Average Non-Current Receivables over 3 years is $3.6 million, with a median of $3.3 million recorded in 2022.
  • Peak annual rise in Non-Current Receivables hit 19.69% in 2022, while the deepest fall reached 19.69% in 2022.
  • Year by year, Non-Current Receivables stood at $4.0 million in 2021, then fell by 19.69% to $3.3 million in 2022, then changed by 0.0% to $3.3 million in 2023.
  • Business Quant data shows Non-Current Receivables for LPCN at $3.3 million in Q2 2023, $3.3 million in Q1 2023, and $3.3 million in Q4 2022.